70. Spinal stenosis Clinical trials / Disease details

Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs021200007	19/06/2020	03/06/2020	MiroTAS	Efficacy and Safety of Mirogabalin for the Treatment as Add-On to NSAIDs in patients with Peripheral Neuropathic Pain caused by Lumbar Spinal Stenosis : Multi-institutional, randomized, open, parallel-design and interventional Study	Lumber Spinal Stenosis	Comparison in the effect and safety of Mirogabalin add-on therapy to NSAIDs and NSAIDs monotherapy for patients with Lumber Spinal Stenosis and administrated of NSAIDs. 1) NSAIDs monotherapy as a study drug are prescribed in accordance with a package insert and each of their administration and dosage is not changed while a study drug is administrated. 2) Mirogabalin add-on therapy to NSAIDs: NSAIDs as a study drug are prescribed in accordance with a package insert and each of their administration and dosage is not changed while a study drug is administrated. Mirogabalin is prescribed as follows in accordance with renal function of a subject. Patients with creatinine clearance more than 60mL/min: Mirogabalin is administrated in dose of 5mg twice a day at the first week. At the next week, Mirogabalin is administrated in dose of 10mg twice a day. At week 5(after Visit3), dose of Milogabalin is increased to 15mg twice a day unless there is no problem with the safety. After that, the dose of Mirogabalin is controlled by 10mg twice a day or 15mg twice a day depending on safety findings. Patients with creatinine clearance 30-60mL/min: Mirogabalin is administrated in dose of 2.5mg twice a day at the first week. At the next week, Mirogabalin is administrated in dose of 5mg twice a day. At week 5(after Visit3), dose of Milogabalin is increased to 7.5mg twice a day unless there is no problem with the safety. After that, the dose of Mirogabalin is controlled by 5mg twice a day or 7.5mg twice a day depending on safety findings. Also, more than 7 days washout period before enrollment is required for target patients administrated of prohibited drugs. If the administration of Mirogabalin is discontinued, down-titration is needed in accordance with the insert package.	Nikaido Takuya	NULL	Complete	>= 20age old	Not applicable	Both	300	N/A	Japan
2	NCT01943435 (ClinicalTrials.gov)	November 20, 2013	8/9/2013	Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)	A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis	Lumbar Spinal Stenosis	Drug: NSAIDs; adjunctive analgesics; adjunctive anti-depressants;Procedure: Lumbar epidural injection;Other: Joint Mobilizations (spine, sacroiliac, hip);Other: Individualized exercises: clinical setting;Other: Group Exercise: community setting	Michael Schneider, DC, PhD	Patient-Centered Outcomes Research Institute	Completed	60 Years	N/A	All	259	N/A	United States
3	JPRN-UMIN000005382	2010/12/01	05/04/2011	Intraoperative perineural infiltration of ropivacaine for acute postlaminectomy pain	Intraoperative perineural infiltration of ropivacaine for acute postlaminectomy pain - Intraoperative perineural infiltration of ropivacaine for acute postlaminectomy pain	lumbar spinal stenosis	General anesthesia and NSAIDs. As a contorol,saline 10ml infiltrate per one interspinal segment. Generalanesthesia and NSAIDs. 0.2%ropivacaine 10ml infiltrate per one interspinal segment. General anesthesia and NSAIDs. From catheter in injury part,administration of 0.2%ropivacaine 6ml/h. Duration of administration:2 days after the operation.	Higashi Ohmiya general hospital	NULL	Complete: follow-up complete	20years-old	75years-old	Male and Female	60	Not selected	Japan